drugset / Trial / NCT00997009

Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer

NCT00997009 ↗

Phase 2 Unknown 108 enrolled National Cancer Institute, Naples
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to assess the activity of a combination of cetuximab (weekly) with carboplatin + paclitaxel (every three weeks) comparing it to chemotherapy alone in terms of event-free survival (EFS).

Timeline

Start
2009-10
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Background Carboplatin Small molecule — Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications